#Sweden #Lund #Hansa Biopharma #imlifidase #Transplant Surgeons

Hansa Biopharma's Virtual Event with Esteemed Transplant Surgeons

On November 12, 2025, Hansa Biopharma will be hosting a significant online event that explores the latest developments in the field of organ transplantation, particularly focusing on the experiences of highly sensitized kidney transplant patients. This event will feature insightful discussions led by renowned transplant surgeons, Professor Robert Montgomery from NYU Langone and Professor Matthew Cooper from the Medical College of Wisconsin.

The event aims to provide deeper insights into the medical journey of patients who face a significant challenge in receiving transplants due to pre-formed antibodies known as donor-specific antibodies (DSAs). The presence of these antibodies complicates their transplant eligibility, reducing their access to compatible organs. Through this event, leading experts will discuss these patients' needs and the clinical advancements that may improve their prospects, highlighting the impactful results from the US Phase 3 ConfIdeS study.

The Phase 3 ConfIdeS Study

The topline results of the ConfIdeS trial, presented by Richard Philipson, Hansa Biopharma’s Chief Medical Officer, reveal promising data regarding the efficacy of Imlifidase, an innovative enzyme treatment designed to help highly sensitized patients. As the trial's lead principal investigator, Dr. Montgomery's expertise in transplant medicine adds immense value to the discussion, while Dr. Cooper's experience in kidney transplantation brings an invaluable perspective to understanding the implications of these results.

The discussion will delve into the current challenges faced by highly sensitized patients and the medical needs that arise from their unique circumstances. The experts will also review the implications of the trial results on current standard of care practices within the US transplant community. Following the presentations, there will be an engaging Q&A session, allowing participants to delve deeper into this critical subject.

The Synergy of Expertise and Innovation

Dr. Robert Montgomery, a pioneer in the field, serves as the Chair of the Department of Surgery and directs the NYU Langone Transplant Institute. Known for his innovative contributions, including the introduction of ‘domino paired donation’ and developing a leading role in xenotransplantation research, he brings a wealth of experience and knowledge to the event. Moreover, Dr. Montgomery is also a heart transplant recipient, which further enriches his perspective on the importance of transplantation.

Dr. Matthew Cooper holds a distinguished role as Chief of Transplantation at the Medical College of Wisconsin and is well-respected in the transplant community. His contributions include serving on boards for the American Society of Transplantation and the National Kidney Foundation, alongside his extensive publication history, with over 260 peer-reviewed manuscripts to his name. His involvement ensures that the event will encompass both practical insights and the latest advancements in kidney transplantation.

Imlifidase: A Game-Changer for Highly Sensitized Patients

Imlifidase represents a groundbreaking approach to desensitize patients who face challenges due to the presence of DSAs. This innovative enzyme, derived from Streptococcus pyogenes, effectively targets and cleaves IgG antibodies, enabling successful transplantation opportunities for those who previously had limited access to donor organs. Its conditional marketing approval in Europe marks a pivotal step forward in improving outcomes for highly sensitized kidney transplant patients.

As roughly 10-15% of all patients on transplant waiting lists are highly sensitized, Imlifidase offers a glimmer of hope for many facing prolonged waiting times, which can significantly increase their mortality risk. The significance of this treatment, especially in the backdrop of an ever-growing waiting list for kidneys, cannot be overstated.

Conclusion

The upcoming virtual event hosted by Hansa Biopharma provides an invaluable platform for addressing the medical needs of highly sensitized transplant patients. By bringing together prominent figures in transplantation, Hansa aims to spark important conversations about innovation and clinical practices that may define the future of organ transplantation. This initiative showcases Hansa Biopharma’s commitment to advancing patient care and fostering hope in the realm of transplantation.

For those interested in participating, click here to join.